| Literature DB >> 15141002 |
Toru Takimoto1, Julia L Hurwitz, Chris Coleclough, Cecilia Prouser, Sateesh Krishnamurthy, Xiaoyan Zhan, Kelli Boyd, Ruth A Scroggs, Brita Brown, Yoshiyuki Nagai, Allen Portner, Karen S Slobod.
Abstract
Although RSV causes serious pediatric respiratory disease, an effective vaccine does not exist. To capture the strengths of a live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xenogeneic vector to deliver the G glycoprotein of RSV. It was previously shown (J. L. Hurwitz, K. F. Soike, M. Y. Sangster, A. Portner, R. E. Sealy, D. H. Dawson, and C. Coleclough, Vaccine 15:533-540, 1997) that intranasal SV protected African green monkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced to clinical trials as a vaccine for hPIV1 (K. S. Slobod, J. L. Shenep, J. Lujan-Zilbermann, K. Allison, B. Brown, R. A. Scroggs, A. Portner, C. Coleclough, and J. L. Hurwitz, Vaccine, in press). Recombinant SV expressing RSV G glycoprotein was prepared by using reverse genetics, and intranasal inoculation of cotton rats elicited RSV-specific antibody and elicited protection from RSV challenge. RSV G-recombinant SV is thus a promising live virus vaccine candidate for RSV.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15141002 PMCID： PMC415788 DOI： 10.1128/JVI.78.11.6043-6047.2004
Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103